Home › Compare › AMPE vs O

AMPE vs O: Dividend Comparison 2026

AMPE yields 1311.05% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AMPE wins by $207537754.81M in total portfolio value
10 years
AMPE
AMPE
● Live price
1311.05%
Share price
$0.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$207537754.85M
Annual income
$180,460,634,612,456.80
Full AMPE calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — AMPE vs O

📍 AMPE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMPEO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMPE + O cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
AMPE pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMPE
Annual income on $10K today (after 15% tax)
$111,438.87/yr
After 10yr DRIP, annual income (after tax)
$153,391,539,420,588.28/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, AMPE beats the other by $153,391,539,416,250.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMPE + O for your $10,000?

AMPE: 50%O: 50%
100% O50/50100% AMPE
Portfolio after 10yr
$103768877.44M
Annual income
$90,230,317,308,779.78/yr
Blended yield
86.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

AMPE
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
Altman Z
-63.7
Piotroski
3/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMPE buys
0
O buys
0
No recent congressional trades found for AMPE or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMPEO
Forward yield1311.05% ✓5.28%
Annual dividend / share$2.00$3.23 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1% ✓
Portfolio after 10y$207537754.85M ✓$34.2K
Annual income after 10y$180,460,634,612,456.80 ✓$5,102.74
Total dividends collected$205538221.53M ✓$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: AMPE vs O ($10,000, DRIP)

YearAMPE PortfolioAMPE Income/yrO PortfolioO Income/yrGap
1← crossover$141,805$131,104.56$10,818$608.16+$131.0K → AMPE
2$1,889,228$1,737,497.51$11,787$741.68+$1.88M → AMPE
3$23,655,368$21,633,893.61$12,946$911.00+$23.64M → AMPE
4$278,471,869$253,160,624.79$14,345$1,127.94+$278.46M → AMPE
5$3,083,213,738$2,785,248,838.88$16,056$1,409.05+$3083.20M → AMPE
6$32,119,606,169$28,820,567,469.38$18,171$1,777.83+$32119.59M → AMPE
7$314,966,468,315$280,598,489,713.88$20,820$2,268.21+$314966.45M → AMPE
8$2,908,568,193,145$2,571,554,072,047.85$24,188$2,929.90+$2908568.17M → AMPE
9$25,305,719,846,817$22,193,551,880,152.03$28,533$3,837.11+$25305719.82M → AMPE
10$207,537,754,848,551$180,460,634,612,456.80$34,235$5,102.74+$207537754.81M → AMPE

AMPE vs O: Complete Analysis 2026

AMPE — Stock

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.

Full AMPE Calculator →

O — REIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this AMPE vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMPE vs SCHDAMPE vs JEPIAMPE vs KOAMPE vs MAINAMPE vs STAGAMPE vs ADCAMPE vs NNNAMPE vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.